Literature DB >> 21321991

Wnt10b activates the Wnt, notch, and NFκB pathways in U2OS osteosarcoma cells.

Ulrike I Mödder1, Merry Jo Oursler, Sundeep Khosla, David G Monroe.   

Abstract

Although osteosarcoma represents the most common bone malignancy, the molecular and cellular mechanisms influencing its pathogenesis have remained elusive. Recent evidence has suggested that the Wnt signaling pathway may play a crucial role in osteosarcoma. This study employed a microarray approach to discover novel genes and pathways involved in Wnt signaling in osteosarcoma. We developed a Wnt10b-expressing cell line using the human U2OS osteosarcoma model (U2OS-Wnt10b) and performed microarray and pathway analyses using parental U2OS cells as control. Differential expression of 1,003 genes encompassing 28 pathways was noted. The Wnt, NFκB, and Notch pathways were chosen for further study based on their known importance in bone biology. Known Wnt-responsive genes Axin-2 (4.9-fold), CD44 (2.1-fold), endothelin-1 (4.2-fold) and sclerostin domain containing-1 (43-fold) were regulated by Wnt10b. The proinflammatory cytokines interleukin-1α and tumor necrosis factor-α, known inducers of NFκB, were upregulated both at the transcript and protein level, and NFκB reporter activity was stimulated 3.8-fold, confirming NFκB activation. Interestingly, genes involved in Notch signaling [Notch-1 (2.4-fold) and Jagged-1 (3.1-fold)] were upregulated, whereas the Notch inhibitor, lunatic fringe, was downregulated (8.2-fold). This resulted in the activation of the classic Notch-responsive genes, hairy and enhancer of split-1 (Hes-1; 2.2-fold) and hairy/enhancer-of-split related with YRPW motif-1 (Hey-1; 2.5-fold). A Hey-1 reporter construct was regulated 9.1-fold in U2OS-Wnt10b cells, confirming Notch activation. Interestingly, Wnt3a failed to induce the Notch and NFκB pathways, demonstrating Wnt-specificity. In conclusion, our data demonstrate that Wnt10b, but not Wnt3a, stimulates the NFκB and Notch pathways in U2OS osteosarcoma cells.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21321991      PMCID: PMC3071438          DOI: 10.1002/jcb.23048

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  46 in total

Review 1.  Wnt signalling in stem cells and cancer.

Authors:  Tannishtha Reya; Hans Clevers
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

2.  Regulation of osteoblastogenesis and bone mass by Wnt10b.

Authors:  Christina N Bennett; Kenneth A Longo; Wendy S Wright; Larry J Suva; Timothy F Lane; Kurt D Hankenson; Ormond A MacDougald
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

3.  Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity.

Authors:  Muzaffer Cicek; Ryuichi Fukuyama; Danny R Welch; Nywana Sizemore; Graham Casey
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

4.  Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors.

Authors:  J Bash; W X Zong; S Banga; A Rivera; D W Ballard; Y Ron; C Gélinas
Journal:  EMBO J       Date:  1999-05-17       Impact factor: 11.598

5.  Wnt-10b directs hypermorphic development and transformation in mammary glands of male and female mice.

Authors:  T F Lane; P Leder
Journal:  Oncogene       Date:  1997-10       Impact factor: 9.867

6.  beta-Catenin activates the growth factor endothelin-1 in colon cancer cells.

Authors:  Tae Hoon Kim; Hui Xiong; Zhuohua Zhang; Bing Ren
Journal:  Oncogene       Date:  2005-01-20       Impact factor: 9.867

7.  Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells.

Authors:  Genevieve M Boland; Geraldine Perkins; David J Hall; Rocky S Tuan
Journal:  J Cell Biochem       Date:  2004-12-15       Impact factor: 4.429

8.  An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.

Authors:  Michelle B Mintz; Rebecca Sowers; Kevin M Brown; Sara C Hilmer; BethAnne Mazza; Andrew G Huvos; Paul A Meyers; Bonnie Lafleur; Wendy S McDonough; Michael M Henry; Keri E Ramsey; Cristina R Antonescu; Wen Chen; John H Healey; Aaron Daluski; Michael E Berens; Tobey J Macdonald; Richard Gorlick; Dietrich A Stephan
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

9.  Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience.

Authors:  D B Glasser; J M Lane; A G Huvos; R C Marcove; G Rosen
Journal:  Cancer       Date:  1992-02-01       Impact factor: 6.860

10.  Frequent beta-catenin abnormalities in bone and soft-tissue tumors.

Authors:  K Iwao; Y Miyoshi; G Nawa; H Yoshikawa; T Ochi; Y Nakamura
Journal:  Jpn J Cancer Res       Date:  1999-02
View more
  24 in total

Review 1.  Update on Wnt signaling in bone cell biology and bone disease.

Authors:  David G Monroe; Meghan E McGee-Lawrence; Merry Jo Oursler; Jennifer J Westendorf
Journal:  Gene       Date:  2011-11-03       Impact factor: 3.688

2.  Osteoprotection Through the Deletion of the Transcription Factor Rorβ in Mice.

Authors:  Joshua N Farr; Megan M Weivoda; Kristy M Nicks; Daniel G Fraser; Brittany A Negley; Jennifer L Onken; Brianne S Thicke; Ming Ruan; Hong Liu; Douglas Forrest; John R Hawse; Sundeep Khosla; David G Monroe
Journal:  J Bone Miner Res       Date:  2017-12-27       Impact factor: 6.741

3.  Osteoclast TGF-β Receptor Signaling Induces Wnt1 Secretion and Couples Bone Resorption to Bone Formation.

Authors:  Megan M Weivoda; Ming Ruan; Larry Pederson; Christine Hachfeld; Rachel A Davey; Jeffrey D Zajac; Jennifer J Westendorf; Sundeep Khosla; Merry Jo Oursler
Journal:  J Bone Miner Res       Date:  2015-08-06       Impact factor: 6.741

Review 4.  Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy.

Authors:  D Matthew Gianferante; Lisa Mirabello; Sharon A Savage
Journal:  Nat Rev Endocrinol       Date:  2017-03-24       Impact factor: 43.330

5.  Notch pathway activation can replace the requirement for Wnt4 and Wnt9b in mesenchymal-to-epithelial transition of nephron stem cells.

Authors:  Scott C Boyle; Mijin Kim; M Todd Valerius; Andrew P McMahon; Raphael Kopan
Journal:  Development       Date:  2011-08-18       Impact factor: 6.868

6.  Examination of ERα signaling pathways in bone of mutant mouse models reveals the importance of ERE-dependent signaling.

Authors:  Kumar Chokalingam; Matthew M Roforth; Kristy M Nicks; Ulrike McGregor; Daniel Fraser; Sundeep Khosla; David G Monroe
Journal:  Endocrinology       Date:  2012-09-26       Impact factor: 4.736

7.  miR-219a-5p Regulates Rorβ During Osteoblast Differentiation and in Age-related Bone Loss.

Authors:  Ruben Aquino-Martinez; Joshua N Farr; Megan M Weivoda; Brittany A Negley; Jennifer L Onken; Brianne S Thicke; McKenzie M Fulcer; Daniel G Fraser; Andre J van Wijnen; Sundeep Khosla; David G Monroe
Journal:  J Bone Miner Res       Date:  2018-10-15       Impact factor: 6.741

8.  Minnelide reduces tumor burden in preclinical models of osteosarcoma.

Authors:  Sulagna Banerjee; Venugopal Thayanithy; Veena Sangwan; Tiffany N Mackenzie; Ashok K Saluja; Subbaya Subramanian
Journal:  Cancer Lett       Date:  2013-03-14       Impact factor: 8.679

9.  Withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells.

Authors:  Joomin Lee; Anuradha Sehrawat; Shivendra V Singh
Journal:  Breast Cancer Res Treat       Date:  2012-09-11       Impact factor: 4.872

10.  Wnt10b Gain-of-Function Improves Cardiac Repair by Arteriole Formation and Attenuation of Fibrosis.

Authors:  David T Paik; Meena Rai; Sergey Ryzhov; Lehanna N Sanders; Omonigho Aisagbonhi; Mitchell J Funke; Igor Feoktistov; Antonis K Hatzopoulos
Journal:  Circ Res       Date:  2015-09-03       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.